(UroToday.com) While there have been transformational changes in first-line therapy for patients with advanced renal cell carcinoma (RCC) in the past three years, these studies have focused on patients with clear cell histology. As a result, there have been little direct data to guide care for patients with non-clear cell histologies and we have had to rely primarily on extrapolation from data derived among patients with clear cell disease. As such, sunitinib has remained the NCCN guideline-recommended first line treatment. First presented at ESMO 2020 and subsequently published, the CheckMate9ER study demonstrated that cabozantinib and nivolumab was associated with improved outcomes compared to sunitinib. In the Kidney and Bladder Poster Discussion session at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, Dr. Lee presented results of a phase II trial of nivolumab and cabozanitinb in patients with non-clear cell renal cell carcinoma (NCT03635892).